Cancer Information Highlights

Cancer Information Highlights





Cancer Information Highlights

Cancer Information Highlights From the National Cancer Institute Updating you about cancer causes, prevention, screening, treatment, coping, and more   New from NCI     Clinical Trial for HIV-Positive Cancer Patients People with HIV are living longer and many are now developing cancers linked with older age. NCI researchers are testing the safety of pembrolizumab in HIV-positive patients with cancer that has come back or not responded to previous treatment. Pembrolizumab is an immune therapy drug.     Moles to Melanoma: Recognizing the ABCDE Features This website uses a series of photographs to help people see how common moles, dysplastic nevi, and melanomas are different. Each series of images is described with its ABCDE features: asymmetry, border, color, diameter (size), and evolving, or changing over time.   Use of PET-CT Scans May Reduce Need for Surgery for Head and Neck Cancer A recent study compared two groups of patients with advanced head and neck cancer. Patients who were monitored with PET-CT scans had fewer operations but similar overall survival rates compared with patients who had neck dissection surgery.     Cervical Cancer Treatment We’ve revised our PDQ summary to include more up-to-date information on risk factors for cervical cancer.     New Drug for Bladder Cancer We’ve added a drug summary about atezolizumab. The Food and Drug Administration (FDA) recently approved it to treat urothelial carcinoma, which is a type of bladder cancer.   Nivolumab for Hodgkin Lymphoma We've updated our drug summary on nivolumab. Nivolumab is now approved by the FDA to treat classical Hodgkin lymphoma in certain patients who have had a stem cell transplant.   Lenvatinib for Kidney Cancer Our drug summary on lenvatinib mesylate has been updated to include the recent approval from the FDA. Lenvatinib mesylate is now approved to treat renal cell carcinoma, the most common form of kidney cancer.   Cabozantinib for Kidney Cancer The Cabometyx brand of cabozantinib-s-malate was recently approved by the FDA to treat renal cell carcinoma. We've updated our drug summary on cabozantinib-s-malate to include this recent approval.

Also of Interest

Survivorship June 5 is National Cancer Survivors Day. Many survivors say that they felt they had lots of support during their treatment, but once it ended it was hard to make a transition to a new way of life. Learn about survivorship after cancer treatment, how to plan for follow-up care, and the physical, emotional, and family issues you may face after treatment.

Prostate Cancer June is Men’s Health Month. Visit our prostate cancer gateway page to learn about prostate cancer treatment, prevention, genetics, causes, screening, clinical trials, research, and statistics.

Long Distance Caregiving Even if you live far away from a loved one with cancer, it's possible for you to give support and help solve problems and coordinate care. Find information about managing the needs of long distance caregivers.